Interleukins, Lymphokines and Lymphoid Neoplasia

  • Richard J. Ford
  • Frances Davis
  • Nicola Kouttab
  • Shashi Mehta
Part of the Developments in Oncology book series (DION, volume 40)


As this volume clearly indicates, human cancer biology has recently focused to a large extent on the area of metastatic spread of tumor cells throughout the body. The delineation of biological consequences of such invasion to the host is for the first time beginning to be understood on more than a phenomenologic basis. Recent studies with a wide variety of experimental tumor systems, as reported here and in the literature, have begun to elucidate many of the biological mechanisms involved in the pathophysiology of neoplasia and have greatly improved our current understanding of the consequences of the spread of tumor cells. Another related area of emphasis has focused on the host’s immune system and its role in preventing the development of neoplasia through various putative immunosurveillance mechanisms available, or in suppressing the progression of the neoplastic process once the surveillance mechanism(s) are either interdicted or circumvented (1,2). This latter area is generally referred to as tumor immunology, dealing with the contest between the host’s immune system and the incipient or established tumor (usually of epithelial or mesenchymal origin). In this Chapter, we would like to discuss a related but somewhat more insidious condition, wherein the tumor is actually present within the host’s immune system. In such conditions of lymphoreticular neoplasia, one does not usually observe metastasis in the conventional sense.


Tumor Cell Population Lymphoid Tumor Human Lymphoid Cell Interdigitating Reticulum Cell Lymphoid Neoplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burnet FM: The concept of immunological surveillance. Prog. Exp. Tumor Res. 13: 1–27, 1970.PubMedGoogle Scholar
  2. 2.
    Old LJ, Stockert E, Boyse E, Kim JH: Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. J. Exp. Med. 127: 523–539, 1968.PubMedCrossRefGoogle Scholar
  3. 3.
    Warnke R, Levy R: Immunopathology of follicular lymphomas: A model of B lymphocyte homing. N. Engl. J. Med. 298: 481–486, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Crowther D, Wagstaff J: Lymphocyte migration in malignant disease. Clin. Exp. Immunol. 5: 413–420, 1983.Google Scholar
  5. 5.
    Thorsby E, Berle E, Nousiainen H: HLA-D region molecules restrict proliferative T cell response to antigen. Immunol. Rev. 66: 39–56, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    LoCascio NJ, Naughton G, Arnold LW, Corley RB: Role of cell surface immunoglobulin in B-lymphocyte activation. Proc. Natl. Acad. Sci. USA 81: 2466–2469, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Maizel AL, Lachman L: Control of human lymphocyte proliferation by soluble factors. Lab. Invest. 50: 369–377, 1981.Google Scholar
  8. 8.
    Cohen S, Pick E, Oppenheim JJ: Biology of the Lymphokines. Academic Press, New York, 1979.Google Scholar
  9. 9.
    Ruscetti FW, Gallo RC: Human T-lymphocyte growth factors; regulation of growth and function of T lymphocytes. Blood 57: 379–394, 1981.PubMedGoogle Scholar
  10. 10.
    Morgan D, Ruscetti FW, Gallo RC: Selective growth of T-lymphocyte from normal human bone marrows. Science 193: 1007–1009, 1976.PubMedCrossRefGoogle Scholar
  11. 11.
    Ford RJ, Mehta SR, Franzini D, Montagna R, Lachman LB, Maizel AL: Soluble factor activation of human B lymphocytes. Nature (London) 294: 261–263, 1981.CrossRefGoogle Scholar
  12. 12.
    Steinman RM, Nussenzweig MC: Dendritic cells: Features and functions. Immunol. Rev. 53: 127–147, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Thorsby E, Nousiainen H: In vitro sensitization of human T lymphocytes to Hapten (TNP)-conjugated and non-treated autologous cells is restricted by self HLA-D. Scand. J. Immunol. 9: 183–189, 1979PubMedCrossRefGoogle Scholar
  14. 14.
    Lachman LB: Human Interleukin 1: Purification and properties. Fed. Proc. Fed. Am. Soc. Exp. Biol. 42: 2639–2645, 1983.Google Scholar
  15. 15.
    Smith KA, Lachman LB, Oppenheim JJ, Favata MF: The functional relationship of the interleukins. J. Exp. Med. 151: 1551–1555, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    Oppenheim JJ, Stadler BM, Seraganian RP, Mage M, Mathieson B: Lymphokines: Their role in lymphocyte responses: Properties of interleukin 1. Fed. Proc. Fed. Am. Soc. Exp. Biol. 41: 258–265, 1981.Google Scholar
  17. 17.
    Ford RJ, Maizel AL: Immunobiology of lymphoreticular neoplasms. IN: Twomey JJ (ed.) The Pathophysiology of Human Immunologic Disorders. Urban and Schwartzenberg, Baltimore, pp. 199–217, 1982Google Scholar
  18. 18.
    Levy R, Warnke R, Dorfman RF, Hamovich J: The monoclonality of human B cell lymphomas. J. Exp. Med. 145: 1014–1028, 1977.PubMedCrossRefGoogle Scholar
  19. 19.
    Glicksman AS, Pajak TF: Early and late effects of lymphoma treatment in the expectation of cure. IN: Rosenberg SA and Kaplan HS (eds.) Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment. Academic Press, New York, pp. 639–661, 1982.Google Scholar
  20. 20.
    Lukes RJ, Parker JW, Taylor CR: Immunologic approach to non-Hodgkin’s lymphomas and related leukemias. Semin. Hematol. 15: 322–338, 1978.PubMedGoogle Scholar
  21. 21.
    Gallo RC, Mann D, Broder S, Ruscetti FW, Maeda M, Reitz MS: Human T cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 79: 3680–3683, 1982.Google Scholar
  22. 22.
    Nilsson K: The nature of lymphoid cell lines and their relationship to the virus. IN: Epstein MA and Achong BG (eds.) The Epstein-Barr Virus. Springer-Verlag, New York, pp. 225–266, 1979.Google Scholar
  23. 23.
    Marcu KB, Harris LJ, Stanton LW, Erikson J, Watt R, Croce CM: Transcriptionally active c-myc oncogene is contained within NIARD, a DNA sequence associated with chromosome translations in B cell neoplasia. Proc. Natl. Acad. Sci. USA 80: 519–523, 1983.PubMedCrossRefGoogle Scholar
  24. 24.
    Aisenberg AC, Wilkes BM, Long JC, Harris NL: Cell surface phenotype in lymphoproliferative disease. Am. J. Med. 68: 206–213, 1980.PubMedCrossRefGoogle Scholar
  25. 25.
    Warnke RA, Link MP: Identification and significance of cell markers in leukemia and lymphoma. Ann. Rev. Med. 34: 117–131, 1983.PubMedCrossRefGoogle Scholar
  26. 26.
    Ford RJ, Cramer M, Davis FM: Identification of human lymphoma cells by antisera to malignancy-associated nucleolar antigens. Blood 63: 559–565, 1984.PubMedGoogle Scholar
  27. 27.
    Harris NL, Data RE: The distribution of neoplastic and normal B-lymphoid cells in nodular lymphomas. Hum. Pathol. 13: 610–617, 1982.PubMedCrossRefGoogle Scholar
  28. 28.
    Maizel AL, Mehta SR, Hauft S, Lachman LB, Ford RJ: Human lymphocyte/monocyte interaction in response to lectin: Kinetics of entry into the S-phase. J. Immunol. 127: 1058–1064, 1981.PubMedGoogle Scholar
  29. 29.
    Ford RJ: Unpublished observations.Google Scholar
  30. 30.
    Kaplan HS: Hodgkin’s disease: Biology, treatment, prognosis. Blood 57: 813–822, 1981.PubMedGoogle Scholar
  31. 31.
    Kaplan HS: Hodgkin’s disease: Unfolding concepts concerning its nature, management and prognosis. Cancer 45: 2439–2474, 1980.PubMedCrossRefGoogle Scholar
  32. 32.
    Ford RJ, Mehta SR, Davis F, Maizel AL: Growth factors in Hodgkin’s disease. Cancer Treat. Rep. 66: 633–638, 1982.PubMedGoogle Scholar
  33. 33.
    Kadin ME: Possible origin of the Reed-Sternberg cell from the Interdigitating reticulum cell. Cancer Treat. Rep. 66: 601–608, 1982.PubMedGoogle Scholar
  34. 34.
    Diehl V, Kirchner H, Schaadt M, Stein H, Gerdes J, Boie C: Hodgkin’s disease: Establishment of four in vitro cell lines. J. Cancer Res. Clin. Oncol. 101: 111–124, 1981.PubMedCrossRefGoogle Scholar
  35. 35.
    Diehl V, Burrichter H, Schaadt M, Hirchner H, Stein H, Gerdes J: Hodgkin’s cell lines: Characteristics and possible pathogenic implications. Hematol. Oncol. 1: 139–147, 1983.PubMedCrossRefGoogle Scholar
  36. 36.
    Levy R, Kaplan HS: Impaired lymphocyte function in Hodgkin’s disease. N. Engl. J. Med. 290: 181–186, 1974.PubMedCrossRefGoogle Scholar
  37. 37.
    Hersh EM, Oppenheim JJ: Impaired in vitro lymphocyte transformation in Hodgkin’s disease. N. Engl. J. Med. 273: 1006–1012, 1965.PubMedCrossRefGoogle Scholar
  38. 38.
    Vanhaelen CP, Fisher RI: Increased sensitivity of lymphocytes with patients with Hodgkin’s disease to concanavalin A induced suppressor cells. J. Immunol. 127: 1216–1220, 1981.PubMedGoogle Scholar
  39. 39.
    Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC: Prostaglandin-producing suppressor cells in Hodgkin’s disease. N. Engl. J. Med. 297: 963–968, 1977.PubMedCrossRefGoogle Scholar
  40. 40.
    Ford RJ, Tsao J, Kouttab N, Sahasrabuddhe CG, Mehta SR: Association of an Interleukin abnormality with the T cell defect in Hodgkin’s disease. Blood (In press).Google Scholar
  41. 41.
    Rappaport RS, Dodge GR: Prostaglandin G inhibits the production of human Interleukin 2. J. Exp. Med. 155: 943–946, 1982.PubMedCrossRefGoogle Scholar
  42. 42.
    Maizel A, Sahasrabuddhe C, Morgan J, Lachman L, Ford RJ: Biochemical separation of a human B cell mitogenic factor. Proc. Natl. Aced. Sci. USA 79: 5998–6002, 1982.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • Richard J. Ford
  • Frances Davis
  • Nicola Kouttab
  • Shashi Mehta

There are no affiliations available

Personalised recommendations